Azelead Overview
- Year Founded
-
2014
- Status
-
Out of Business
- Employees
-
3
- Latest Deal Type
-
Liquidation
Azelead General Information
Description
Developer of decision support models designed to study response to a therapeutic treatment. The company's models are developed using zebrafish, a completely transparent fish that allows real-time visualization of the efficiency of a drug and its side effects on the body, enabling pharmacists to prevent the appearance of metastatic cancers and help the development of effective and less toxic anti-cancer drugs.
Contact Information
Website
www.azelead.comCorporate Office
- 377 rue du Professeur Blayac
- 34080 Montpellier
- France
Corporate Office
- 377 rue du Professeur Blayac
- 34080 Montpellier
- France
Azelead Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 5. Bankruptcy: Liquidation | 06-Jul-2023 | Completed | Bankruptcy: Liquidation | |||
| 4. Accelerator/Incubator | 01-Sep-2021 | Completed | Generating Revenue | |||
| 3. Angel (individual) | 01-Jul-2016 | Completed | Generating Revenue | |||
| 2. Angel (individual) | Completed | Generating Revenue | ||||
| 1. Accelerator/Incubator | Completed | Generating Revenue |
Azelead Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Preference |
Azelead Patents
Azelead Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| FR-3062796-A1 | Use of a compound belonging to the diuretics family to treat cancer | Active | 10-Feb-2017 | ||
| FR-3062796-B1 | Use of a compound belonging to the diuretics family to treat cancer | Inactive | 10-Feb-2017 | ||
| EP-3579839-A1 | Use of a compound of the diuretics class for treating cancer | Inactive | 10-Feb-2017 | ||
| US-20230137849-A1 | Use of a compound of the diuretics class for treating cancer | Inactive | 10-Feb-2017 | ||
| WO-2018146390-A1 | Use of a compound of the diuretics class for treating cancer | Inactive | 10-Feb-2017 | A61K31/549 |
Azelead Signals
Azelead FAQs
-
When was Azelead founded?
Azelead was founded in 2014.
-
Where is Azelead headquartered?
Azelead is headquartered in Montpellier, France.
-
What is the size of Azelead?
Azelead has 3 total employees.
-
What industry is Azelead in?
Azelead’s primary industry is Decision/Risk Analysis.
-
Is Azelead a private or public company?
Azelead is a Private company.
-
What is Azelead’s current revenue?
The current revenue for Azelead is .
-
How much funding has Azelead raised over time?
Azelead has raised $219K.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process